DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Outlook Therapeutics Announces Agreements To 'Streamline' Capital Structure And Regain 100% Ownership Of Any Future Net Profits For ONS-5010

Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in

Benzinga · 01/28/2020 13:02

Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into agreements with BioLexis Pte. Ltd. ("BioLexis"), its largest stockholder, and MTTR, LLC ("MTTR"), its development partner for ONS-5010, to better align the interests of all parties with the Company's common stockholders and support the continued development of ONS-5010.